US › Healthcare

IGC Pharma, Inc. (IGC)

US · Healthcare · Biotechnology

$0.20+5.26%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$265,000

Revenue YoY

-19.2%

Net profit

$-2.9M

EPS

$-0.03

EPS estimate

$-0.02

Net margin

-1,107.9%

EPS came in at -0.03 against a street estimate of -0.02 — a miss of 50.0%.

Key statistics

Market cap

$20.7M

Forward P/E

0.0

P/B

3.19

Book value

$0.06

EPS (TTM)

$-0.07

52-week high

$0.40

52-week low

$0.18

50-day MA

$0.26

200-day MA

$0.28

Beta

0.55

Analyst view

Analysts rate IGC Pharma, Inc. a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $6.00.

Shareholding

Insiders

9.17%

Institutions

19.69%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for IGC Pharma, Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.